The effects of NSAID on the matrix of human articular cartilages.
The present paper presents data obtained over a 12 year period, on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic (N) human cartilages using a standardised in vitro method. When the relative metabolic (synthetic/repair activity) of these human cartilages was compared, it was demonstrated that in osteoarthritis (OA) and rheumatoid arthritis (RA) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages. However, the turnover rate of matrix was not significantly different between Non-arthritic and OA, but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus. The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis. 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis. Consideration of the results in this study and from published material, led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages: 1. Those such as Aceclofenac, Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam, Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and, 3. Those like Naproxen, Ibuprofen, Indomethacin, Nimezulide which significantly inhibit matrix synthesis. It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity. Other NSAIDs may also inhibit IL1 synthesis or release, but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism. These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo.
Dingle
J T
JT
Addenbrooke's Hospital, UK-Cambridge.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000145:classification / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000473:pathology*; D002358:Cartilage, Articular / Q000187:drug effects* / Q000473:pathology; D019902:Chondrocytes / Q000187:drug effects / Q000473:pathology; D003094:Collagen / Q000378:metabolism; D005109:Extracellular Matrix / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000473:pathology*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006025:Glycosaminoglycans; D007375:Interleukin-1; D003094:Collagen